Avecho Biotechnology Limited
OTC: AVEFF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul Gavin
- Employees
- 15
- Headquarters
- Clayton, Australia
- IPO year
- 2018
- Market cap
- $13.4M
- Website
- https://avecho.com.au
Loading AVEFF…
Loading profile data…Frequently asked questions about AVEFF
What does Avecho Biotechnology Limited (AVEFF) do?
Avecho Biotechnology Limited is an Australian-based firm specializing in the development, production, and sale of various products. Central to its operations is the proprietary and patented Targeted Penetration Matrix (TPM) drug delivery system, which the company leverages across the pharmaceutical, skincare, animal health, and nutrition industr...
Where does AVEFF trade?
Avecho Biotechnology Limited (AVEFF) trades on the Other OTC.
What sector is AVEFF in?
Avecho Biotechnology Limited (AVEFF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Avecho Biotechnology Limited?
Paul Gavin is the chief executive officer of Avecho Biotechnology Limited (AVEFF).
Where is Avecho Biotechnology Limited headquartered?
Avecho Biotechnology Limited is headquartered in Australia.
Does AVEFF pay a dividend?
Avecho Biotechnology Limited (AVEFF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AVEFF go public?
Avecho Biotechnology Limited (AVEFF) completed its initial public offering in 2018.